ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EDEN Eden Research Plc

4.60
-0.25 (-5.15%)
23 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -5.15% 4.60 4.50 4.70 4.85 4.60 4.85 123,819 15:06:53
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -10.95 24.53M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.85p. Over the last year, Eden Research shares have traded in a share price range of 3.20p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £24.53 million. Eden Research has a price to earnings ratio (PE ratio) of -10.95.

Eden Research Share Discussion Threads

Showing 1851 to 1871 of 17825 messages
Chat Pages: Latest  77  76  75  74  73  72  71  70  69  68  67  66  Older
DateSubjectAuthorDiscuss
15/6/2016
19:14
LR2I find it more odd that you guys have no real problems with the TT deal and Supersonico gets frenzied about TW/SK and what they say/didn't say rather than real issuesOn the subject of company attackers (and I have no problem with those who attack on BB's or with shorters, it keeps the market real) there's only one way you get the better of them and that's where you continue to hold or even add to your investment if you are convinced of the story, then of course the company needs to deliver on its promises.
quazie12
15/6/2016
17:55
It still strikes me as odd Quazie that you only made one single posting here during the 10 years you say you held Eden but have subsequently made 105 more posts since you say you sold out.

To give you your due however, I don't ever recall you saying anything about Eden being fraudulent.

lr2
15/6/2016
17:31
Q12, fair enough, I wasn't suggesting you had anything to do directly with SK but you do seem to be influenced by him. Maybe you just believe what he says, which is your choice.

Regarding the TT deal, yes shareholders were diluted but Eden needed cash for the reasons I mentioned. Remember the shares were issued at a higher share price than it has been since. As for the other comments on the deal I don't agree they are relevant or important - the valuation and revenue treatment are red herrings but I have no intention of getting into a debate about it. Time will show.

redhill9
15/6/2016
16:51
RedhillFor the avoidance of doubt, i have nothing to do with SK whatsoever. Further, i have not to my knowledge, ever described the TT deal as fraud, that is a word used by others. Im sure that will set some sad wee troll off trolling over all my earlier posts then smugly repost on here, go ahead sad POS.I think the company have behaved like many AIM co's in the past, more than highly disrespectful to shareholders, overly generous to themselves, claiming constantly about wins and results in the face if minimal revenues. Nothing new and no cause for bitterness.I was a long term holder of Eden until recently, 10 years actually and yes I lost money. I am not bitter, i just lost faith. Didnt like TT transaction, the fact that someone made £320k from the deal, we got diluted again, the shares were probably dumped in the market, i don't believe in the valuation of TT at £3m + and Didnt like the £600k revenue treatment. Still waiting however for the company to discharge their legal obligations and submit the Independent Valuation to Comanies House at time of writing.Why am I on here ? Probably largely due to the troll like attacks from a number of posters when i dared to post something negative back in Feb. I thought "Fk you" for attacking a genuine poster, "fk you" for posting utter sh*te, spinning bullish nonsense to each other giving the impression that anyone who hadnt filled their boots was missing the investment of the century. Irrespective, i have said this before, i genuinely hope genuine LT holders get a result one day. I moved on and dont regret it.Q12
quazie12
15/6/2016
13:24
Hey Q12/SK/Frothy


How did Shorecap manage to hide the TT deal from LivingBridge.

.....................................................................................
mean while at Sharepopets HQ

Hey SK

Yes Frothy

Remember don't mention Shore Cap.
Supersonico has asked a question which totally blows my Fraud narrative.
and I can't answer it without getting into deep pooh with Shore Cap.
You and Q12 keep banging on about TT ..I preferred it when the deluded maggot posted in Greek.



OK Frothy

supersonico
15/6/2016
13:18
Gemstar2Another troll with a personal attack MO. Thank you for your valuable contribution of criticism of posters and sweet FA else. Just what has the sophistication of my investment ability got to do with anything at all ?You are making a total fool of yourself mate and i suppose its my fault now that your investment is tanking ?Q12
quazie12
15/6/2016
12:32
Quazie, if you are Big Al then you are a very sophisticated investor

And I would only remind you of the words of the beautiful Charlotte Lucas

'not to be a simpleton, and allow her fancy for Wickham to make her appear foolish in the eyes of a man of ten times his consequence '

Wise words

gemstar2
15/6/2016
12:16
Shore Capital comment on today's news:

EDEN RESEARCH+ (EDEN, House stock at 9p) Label extensions for 3AEY in Spain and Greece. Eden Research (‘Eden’) has announced that, together with its commercialisation partners in Spain (Sipcam Iberia) and Greece (Redestos Group), it has been granted label extensions for the use of 3AEY for a new disease target in Spain and number of additional minor uses in Greece, beyond the original designation for the prevention and treatment of botrytis in table and wine grapes.

In Spain, 3AEY (locally marketed as "ARAW" by Sipcam) has been additionally approved for use in the control of vine powdery mildew. Powdery mildew is one of the most challenging and widespread fungal diseases of grapevines in the world. Powdery mildew manifests itself as a powdery growth on the tissue of the vine and affects both table grapes and wine grapes causing significant crop losses and impacting the quality of wine. In Greece, the authorities have expanded the approval for the use of 3AEY (marketed as Mevalone in Greece and the Balkan states) in the treatment of botrytis on field and greenhouse aubergines, kiwis, pomegranates and fresh onions. Combined, these crops cover more than 14,000 hectares in Greece.

These approvals are the first milestone in the expansion of regulatory clearance for 3AEY outside of the initial authorisation for the prevention and cure of botrytis on table and wine grapes. Together with Redestos Group, Eden is also pursuing authorisation for 3AEY in several countries outside of the EU Southern Zone, and these registrations will be granted in due course, subject to regulatory process and approval.

Today’s announcement follows on from the recent FY2015A preliminary results which highlighted Eden reaching a number of important milestones during the year. The company now looks well positioned with a strong balance sheet post the recent capital raising to deliver further progress in FY2016F. House Stock.

+Shore Capital Stockbrokers Limited acts as broker and Shore Capital & Corporate Limited acts as NOMAD to Eden Research. In line with its conflicts of interest policy, Shore Capital does not make formal recommendations on house stocks.

Phil Carroll – 0151 600 3711

the prophet
15/6/2016
12:03
Redhill 9

So effectively you are saying that you are happy with Terpenetech deal ? Wow you are one easily please PI then.

I don't post anything original, so what, not many do, unless of course you count ramptastic sh!te as original thinking which you probably do.

Q12

quazie12
15/6/2016
09:19
excellent news. M.cap here look far too low at the mo, picked a few more up yesterday. When you consider just the cost let alone the time of registering a biopesticide is $20m and Eden have three such approvals,then without considering market approvals, market size, other products in the pipeline, commercial tie ups etc etc, then valuation here is very modest, imo.
With money in the bank, a strategic investor on the bod, more deals and news to come then things look good.

the prophet
15/6/2016
08:44
Probably not immediately material, but good news nonetheless and another step forward.

Label extensions for 3AEY in Spain and Greece

Date: 7:00 am, 15 Jun 2016

RNS Number : 2059B
Eden Research plc
15 June 2016

Eden Research Plc ("Eden" or "Company")

Label extensions for 3AEY in Spain and Greece

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that, together with its commercialisation partners in Spain (Sipcam Iberia) and Greece (Redestos Group), it has been granted label extensions for the use of 3AEY for a new disease target in Spain and number of additional minor uses in Greece, beyond the original designation for the prevention and treatment of botrytis in table and wine grapes.

In Spain, 3AEY (locally marketed as "ARAW" by Sipcam) has been additionally approved for use in the control of vine powdery mildew. Powdery mildew is one of the most challenging and widespread fungal diseases of grapevines in the world. Powdery mildew manifests itself as a powdery growth on the tissue of the vine and affects both table grapes and wine grapes causing significant crop losses and impacting the quality of wine. In Greece, the authorities have expanded the approval for the use of 3AEY (marketed as Mevalone in Greece and the Balkan states) in the treatment of botrytis on field and greenhouse aubergines, kiwis, pomegranates and fresh onions. Combined, these crops cover more than 14,000 hectares in Greece.

These approvals are the first milestone in the expansion of regulatory clearance for 3AEY outside of the initial authorisation for the prevention and cure of botrytis on table and wine grapes. Together with Redestos Group, Eden is also pursuing authorisation for 3AEY in several countries outside of the EU Southern Zone, and these registrations will be granted in due course, subject to regulatory process and approval.

redhill9
14/6/2016
20:33
SSDo you think Livingbridge really gave a Sh1t about the TT deal if it occurred before they invested ? The only real losers were us shareholders, hence the reason I baled out. Without doubt they will have discounted the licensing revenue and stake in TT, (as the market seems to have done ever since) and were prepared simply to take a punt on the story but get a place on the Board to police their investment at the same time.
quazie12
14/6/2016
15:26
We are waiting for the FRC 127 to make a call on TT
3 lots of DD say it was ok
1 Vendetta laced DD says it's not... we'll see.

In the mean time I puzzled and repeat the question.


How did Shorecap manage to hide the TT deal from LivingBridge ?


on a positive note fellas well done for not using the D word..much appreciated

supersonico
14/6/2016
14:44
How are you coping in Africa these days SK?
gemstar2
14/6/2016
13:00
Eden Shareprice tanking! Could it be that yet more people have lost faith as it ducks all questions about the Terpenetech fraud. Gagging its supporters so they cannot answer the questions and can only cling to other peoples due diligence as an excuse for not bothering to do their own research.

I don't know why it happens with such regularity that people who should know better put on rose tinted glasses and ignore the obvious, but QPP, GBO and Eden are just 3 of many examples.

sweet karolina
14/6/2016
12:57
Hi SKYes I did actually get a prompt and courteous response from an officer of the company who said that the omission is in the process of being rectified. I checked this morning and the Valuation is not yet online, it may take a few days.Q12
quazie12
14/6/2016
10:05
Q12

Have you had any sort of answer back from the company on that Terpenetech independent valuation?

I hope you are not holding your breath waiting for it. The chances are they will not even have the courtesy to acknowledge your e-mail. They will most likely follower the fraudsters play book to the letter and completely ignore you.

sweet karolina
13/6/2016
20:07
Hey SK/Q12/FROTHY.

This is the question again.. just in case you missed it.. since your so convinced of the TT fraud and Frothy vendetta DD.

How did Shorecap manage to hide the TT deal from LivingBridge ?

Good luck keeping out of the Swing..

supersonico
13/6/2016
20:01
Interesting Monet.. That Deluded word comes up again. it's certainly popular.

My question is bound either to be ignored or have Delusional in the answer.

Place your bets Here....

supersonico
13/6/2016
19:26
Have a look at the youtube video. What a drunken bum why would anyone take any notice of him. Lol
monet
13/6/2016
19:18
Q12/ SK,

Shore CAP have not resigned, they have arranged the LivingBridge deal and Frothy is 100% confident that the TT deal is a Fraud.

How did Shorecap manage to hide the TT deal from LivingBridge ?

supersonico
Chat Pages: Latest  77  76  75  74  73  72  71  70  69  68  67  66  Older

Your Recent History

Delayed Upgrade Clock